Production of human blood group B antigen epitope conjugated protein in *Escherichia coli* and utilization of the adsorption blood group B antibody

Wenjing Shang¹², Yafei Zhai¹, Zhongrui Ma¹, Gongjin Yang¹, Yan Ding¹, Donglei Han¹, Jiang Li¹, Houcheng Zhang¹, Jun Liu¹, Peng George Wang¹, Xian-wei Liu¹* and Min Chen¹*

**Abstract**

**Background:** In the process of ABO-incompatible (ABOi) organ transplantation, removal of anti-A and/or B antibodies from blood plasma is a promising method to overcome hyperacute rejection and allograft loss caused by the immune response between anti-A and/or B antibodies and the A and/or B antigens in the recipient. Although there are commercial columns to do this work, the application is still limited because of the high production cost.

**Results:** In this study, the PglB glycosylation pathway from *Campylobacter jejuni* was exploited to produce glycoprotein conjugated with *Escherichia coli* O86:B7 O-antigen, which bears the blood group B antigen epitope to absorb blood group B antibody in blood. The titers of blood group B antibody were reduced to a safe level without changing the clotting function of plasma after glycoprotein absorption of B antibodies in the plasma.

**Conclusions:** We developed a feasible strategy for the specific adsorption/removal of blood group antibodies. This method will be useful in ABOi organ transplantation and universal blood transfusion.

**Keywords:** Immunoadsorption, Blood group B antigen, Conjugated glycoprotein, *E. coli* O-antigen, PglB

**Background**

The ABO blood group system is the most important blood type system in humans. Blood type incompatibility means the exposure of A or B antigen to a person who has antibodies against these antigens [1]. These antibodies act as haemagglutinins, which cause blood cells to clump and break apart, and can even cause death when large amounts of such cells are encountered after transfusion or organ transplant. Removal of anti-A and/or B antibodies from plasma is a promising method to overcome hyperacute rejection and allograft loss [2]. Several protocols have been employed to remove antibodies or antibody-producing cells in the process of ABOi organ transplantation [3], among which immunoadsorption has attracted more attention because of its specificity. The most commonly used immunoadsorbers are glycosorb columns with A/B blood group antigens linked to a sepharose matrix [4, 5]. Unfortunately, A and B blood group antigens are difficult to acquire and immobilize [6].

At present, most A/B antigens used in glycosorb columns are synthesized by chemical methods or enzymatic synthesis. One of the most difficult steps in the chemical synthesis of well-defined oligosaccharide antigens is the stereospecific formation of glycosidic linkages between monosaccharide units [7]. Enzymatic synthesis utilizing the corresponding glycosyltransferase is limited by the availability of enzymes and the cost of activated sugar donors [8]. Accordingly, it is necessary to find a low-cost and highly-effective method to produce A/B antigens to remove anti-A/B antibodies from plasma.
The O-antigen in *Escherichia coli* (E. coli) O86:B7 has been shown to possess high human blood group B activity because of the structural similarity between the O-antigen and human blood group B antigen epitope [9–11] (Fig. 1). Therefore, *E. coli* O86:B7 can be a potential cell factory of B antigens. We plan to obtain a type of glycoprotein loaded with this O-antigen that can be used to remove the A/B antibody from plasma. The oligosaccharyl transferase PglB from *Campylobacter jejuni* (*C. jejuni*) can transfer a wide range of polysaccharides from undecaprenyl-pyrophosphate (Und-PP) linked precursors to the asparagine of the consensus sequence D/E-X-N-Y/S/T (X, Y ≠ Proline) of the carrier protein in the periplasm [12, 13]. The N-glycosylation pathway from *C. jejuni* in recombinant *E. coli* has been shown to be a simple method for producing glycoprotein [12].

In our work, the N-glycosylation pathway of *C. jejuni* was used to produce glycoprotein conjugated with the O86 O-antigen (Fig. 2). The O86 O-antigen conjugated-protein could adsorb anti-B antibody in the plasma, and the parameters of coagulation were not affected after the adsorbing process. Furthermore, it would have potential use in universal blood transfusion and may also be used in ABOi organ transplantation.

### Results and discussion

**The production and detection of MBP_{mut}-OPS (O86:B7) bioconjugates**

To obtain glycoprotein loaded with OPS of O86:B7, PglB from *C. jejuni* was cloned into *E. coli* O86:B7 to transfer the O-antigen onto the protein, resulting in a kind of glycoprotein with OPS.

In *E. coli*, the OPS is transferred to lipid A by the WaaL enzyme to produce LPS. To effectively conjugate the OPS on a protein by PglB, the *waaL* gene was deleted from *E. coli* O86 using a λ-Red recombination system. The *waaL* gene deletion was confirmed using test primer pair t-waaL-F/t-waaL-R, which could amplify across the deletion area. Furthermore, ladder straps were observed on the SDS-PAGE gel of LPS from wild *E. coli* O86, while no straps were observed in the lane of the LPS extracted from *E. coli* O86 ΔwaalL, which indicated that the LPS of *E. coli* O86 ΔwaalL had a low degree of polymerization (Fig. 3). Therefore, we successfully obtained a strain of *E. coli* O86:B7 without the *waal* gene.

![Fig. 1](Image1)  
**Fig. 1** The O-antigen repeat unit structure of *E. coli* O86:B7. The human blood group B antigen epitope is labeled in a dashed box

![Fig. 2](Image2)  
**Fig. 2** The scheme of the production of MBP_{mut}-OPS and its application

![Fig. 3](Image3)  
**Fig. 3** Silver staining result of LPS. The silver staining was detected on 12 % gel. Line 1: LPS extracted from *E. coli* O86ΔwaalL; Line 2: LPS extracted from *E. coli* O86 wild type; M: protein Marker
Maltose-binding protein (MBP) was selected as a carrier protein for OPS with B antigen activity. MBP is expressed in the periplasm of *E. coli* by the malE gene [14], which is generally used as a tag for expression and purification of foreign recombinant proteins [15] with an Amylose-Resin column. MBP without an N-glycosylation site was modified to MBP_mut with four consensus sequences at the C terminal for loading with blood group B antigen epitope by cloned PglB in *E. coli* O86 ΔwaaL. The glycosylated MBP_mut (i.e. MBP_mut-OPS) and unglycosylated MBP_mut were purified from *E. coli* O86 ΔwaaL with or without the plasmid pACT3-PglB and identified by SDS-PAGE (Fig. 4a) and western blot using anti-His antibody (Fig. 4b), anti-MBP antibody (Fig. 4c) and anti-O86 OPS antibody (Fig. 4d), respectively.

When probed using the anti-His and anti-MBP antibody, a ladder of bands appeared on the blot when MBP_mut was expressed in *E. coli* O86 ΔwaaL with PglB (Fig. 4 lane 1), indicating that the protein was conjugated with multi-units of OPS (MBP_mut-OPS), while unglycosylated MBP_mut expressed in *E. coli* O86 ΔwaaL without PglB showed only one band with a molecular weight of 44 kDa, as expected (Fig. 4 lane 2). During the process of western blot, O86 antiserum instead of monoclonal anti-O86 antibody was used to determine the O-antigen activity of MBP_mut-OPS. Therefore, nonspecific reaction might occur in form of the lightgray band on the western blot. These results were consistent with the finding that OPS had typical variability of chain length with different degrees of polymerization [16]. Furthermore, conjugation of OPS on MBP_mut was confirmed by MALDI-TOF mass spectrometry. As expected, the molecular weight of MBP_mut-OPS (47,898.93 Da) was higher than that of MBP_mut (44,017.39 Da) (Additional file 1: Figure S1). The average number of OPS repeat units in purified MBP_mut-OPS was four based on the molecular weight of one repeat unit of OPS (894 Da) and MBP_mut (44017 Da). Moreover, 1.5 mg MBP_mut-OPS was purified from 1 L of fermentation, which provided a way to obtain a large yield of glycoproteins using *E. coli* O86. We believe that the yield can be improved after optimizations such as culture conditions, fermentation method. Still, the cost of this approach to produce B-antigen absorption material is much lower than tradition method which includes enzymatic synthesis of B-antigen saccharide using the corresponding glycosyltransferases because of the limited availability of enzymes, the high cost of activated sugar donors, etc.

**Ability of MBP_mut-OPS conjugates to bind to blood group B antibody**

An ELISA assay was conducted to measure the ability of MBP_mut-OPS conjugates to bind with anti-A/B antibody. Unglycosylated MBP_mut without blood group activity was used as a negative control. The MBP_mut-OPS can be recognized by the anti-B antibody (Fig. 5b), but not by the anti-A antibody (Fig. 5a). No binding between unglycosylated MBP_mut and anti-A/B antibody was detected. These results suggested that MBP_mut-OPS could bind anti-B antibody.

**Specific absorption of blood group B antibody in the plasma**

Based on the results of ELISA, MBP_mut-OPS was applied to remove anti-B antibodies from blood group O and group A plasma as a B antigen. The removal rates of B antibody in plasma increased as increasing amounts of glycosylated MBP_mut were added. The average blood group anti-B antibody titer of plasma samples of blood group O decreased from 64 to 4 (Fig. 6a) after treatment with MBP_mut-OPS (320 μg/mL). A previous report indicated that the antibody titer of plasma samples ≤8 is compliant with the restricting final titer for undergoing
surgery [17]. Analogously, upon evaluation of the plasma of blood group A, the titers of all samples decreased to a safe level of 4 after adsorption with a final concentration of 160 μg/mL MBPmut-OPS (Fig. 6b).

To investigate the effects of MBPmut-OPS on blood coagulation, the parameters of PT, APTT, TT, and Fib were detected within 4 h of blood withdrawn to citrate. None of the above parameters in the treated sample with MBPmut-OPS differed significantly from the control and levels remained normal (Fig. 6c). These results demonstrated that MBP mut-OPS could absorb anti-B antibody effectively and did not affect the coagulation properties of the plasma. Thus, the purified glycoprotein with blood group B epitope has great potential for clinical applications. MBP with O-antigen of E. coli O86 could be used to remove anti-B antibody from group O or A in emergency transfusions without strict matches. The produced MBPmut-OPS in E. coli O86 ΔwaaL will contribute significantly to the development of a method for universal blood transfusion. Furthermore, for actual clinical applications, the endotoxin of the glycoprotein produced from E. coli cells should be removed to a safety level, which will be taken into consideration in our following study.

**Conclusions**

This study successfully glycosylated MBP with B antigen using a novel one-shot approach. In the system, large quantities of glycoproteins are produced and have great potential for further clinical development in many fields including ABOi organ transplantation and universal blood transfusion. In addition, glycoprotein with blood group antigens could also be used as research tools or alternative drugs for infection or other diseases associated with blood group antigens. A similar strategy could extend to blood group A antigen since anti-A agglutinins were reported to be absorbed by an A active E. freundii [18].

**Methods**

**Bacterial strains, plasmids and growth condition**

*Escherichia coli* O86:B7 (ATCC 12701) was obtained from American Type Culture Collection (Rockville, MD). Commercially available IgM monoclonal anti-B antibody (obtained from clone HEB-29) was purchased from Merck Millipore (Billerica, USA). All strains and plasmids used in this study were listed in Additional file 1: Table S1. All strains were grown in Luria–Bertani broth (LB) at 37 °C. *E. coli* DH5α and O86 were used for plasmids cloning and glycoprotein expression experiments, respectively. Ampicillin (100 μg/mL), 50 μg/mL kanamycin and 34 μg/mL chloramphenicol were added to the media for selection as needed. Plasmids pKD4, pKD46 and pCP20 were used for the deletion of the gene coding for the O-polysaccharide ligase WaaL of *E. coli* O86. Plasmid pACT3 and pBAD24 were used for the expression of PglB and MBP protein, respectively.

**Knockout of waaL gene of *E. coli* O86**

The waaL gene of *E. coli* O86 was knocked out to obtain O86 ΔwaaL: FRT using λ-Red recombination system. Briefly, using plasmid pKD4 as template, the kanamycin-resistant gene flanked by homologues of waaL gene was amplified by PCR with knockout primers. When induced by L-arabinose, plasmid pKD46 could express three recombinant proteins (Exo, Beta, Gam) of λ-prophage, which assisted the replacement of waaL gene with kanamycin-resistant gene. Subsequently, the kanamycin-resistant gene was eliminated by FLP-promoted recombination system using plasmid pCP20 and the *E. coli* O86 ΔwaaL was obtained successfully. The knockout primers (k-waaL-F, k-waaL-R) and test primers (t-waaL-F, t-waaL-R) used in the knockout experiments were listed in Additional file 1: Table S1. The extraction of LPS was carried out according to the instruction of LPS extraction kit (iNtRON Biotechnology, KOREA). The silver staining experiment was performed as reported previously [19].

**Construction of recombinant plasmids**

In order to ensure the successful glycosylation of MBP by PglB, the consensus sequence D-Q-N-A-T was repeated four times and inserted at the C terminal of MBP.
Overlap PCR was used to amplify the malE<sub>mut</sub> gene with primers malE-F, malE-R1, malE-R2 and malE-R3 (Additional file 1: Table S1). Restriction sites for SalI and HindIII at their 5′ ends of primers were used for the insertion of the modified gene into the vector pBAD24, and thus the plasmid pBAD24-malE<sub>mut</sub> was obtained with a 6× His tag (i.e. N-HHHHHH-C) between SmaI and SalI of pBAD24 (Induced by L-arabinose). Likewise, the pglB gene from C. jejuni NCTC 11168 was inserted between SmaI and SalI of plasmid pACT3 (Induced by IPTG) and the plasmid pACT3-PglB was obtained.

**Glycoprotein expression and purification**

The recombinant plasmids pBAD24-malE<sub>mut</sub> and pACT3-PglB were co-transformed into E. coli O86 ΔwaaL to obtain an engineering strain with the ability to produce MBP<sub>mut</sub>-OPS bioconjugates. Plasmid containing MBP<sub>mut</sub> gene was transformed into E. coli O86 ΔwaaL to produce unglycosylated MBP<sub>mut</sub> as a control. E. coli O86 ΔwaaL transferred with pBAD24-malE<sub>mut</sub> and pACT3-PglB was grown in 50 mL LB broth at 37 °C for 16 h, with shaking. Cultures were then inoculated 1/100 into 1 L TB broth and further grown at 37 °C with shaking until OD<sub>600</sub> reached 0.6. Subsequently, 0.1 % (w/v) L-arabinose and 50 μM IPTG were added to induce the expression of MBP and PglB, respectively. After further incubation at 28 °C for 6 h, 0.1 % (w/v) L-arabinose was added again for continuous induction of MBP.

After that, cells were pelleted by centrifugation at 10,000 rpm for 15 min at 4 °C, and then resuspended in lysis buffer (50 mM PBS, 200 mM NaCl, 5 % glycerin, pH 7.4). The supernanant of cells after ultrasonic lysates was purified using pre-equilibrated Ni-nitrilotriacetic acid (NTA) columns under native conditions. Washing buffer (50 mM PBS, 200 mM NaCl, 5 % glycerin, 50 mM imidazole, and pH 7.4) and elution buffer (50 mM PBS, 200 mM NaCl, 5 % glycerin, 250 mM imidazole, and pH 7.4) were sequentially used. Fraction containing the purified glycoconjugate was collected and then desalted using centrifugal filter (Amicon<sup>®</sup> Ultra-15, Milipore) against
PBS (PH 7.4). The concentration of the proteins was measured with Bradford method.

Detection of purified glycoprotein
Western blotting was used to detect MBP and MBPmut-OPS expression. Samples were separated on 8 % SDS-denatured polyacrylamide gel and were then transferred onto nitrocellulose membrane. Membranes were blocked in 3 % BSA solution for 1 h at room temperature, and then were incubated with anti-hexahistine (anti-His) monoclonal antibody and anti-MBP monoclonal antibody (Beyotime Biotechnology, China), as well as anti-O86 O-antigen polyclonal antibody (Tianjin Biochip Corporation, China), respectively overnight at 4 °C. The secondary antibodies with a horseradish peroxidase (HRP) (Abcam, UK) were used subsequently. The image acquisition was finished by Flour ChemQ (Proteinsimple, US). MALDI-TOF result was analyzed by the MALDI-TOF mass spectrometer (AXIMA Confidence, SHIMAZU, Japan) with sinapic acid as the matrix (50 % ACN, 50 % H2O, 0.1 % TFA).

Binding ability measurement of glycoprotein and anti-B antibody
Polystyrene microtiter plates were coated by the purified proteins MBP/MBPmut-OPS from E. coli O86 at different concentration overnight at 4 °C. The plates were blocked with 2 % BSA in PBS buffer for 2 h at room temperature. After being washed three times with PBST (PBS, 0.05 % Tween-20), the plates were incubated with anti-B antibody diluted to 1:20 for 2 h, or with anti-A antibody (1:20) as control. After washing, the secondary antibody goat anti-mouse IgM conjugated to HRP (1:20,000) (Abcam, UK) was added and maintained for 1 h. Finally, the TMB substrate was used to develop the signal and 1 M HCl was used to terminate the reaction, and the OD was measured at 450 nm on Bio-Rad680 microplate reader (Hercules, California, USA).

Detection of the B antibody titer and coagulation parameters in the plasma
All blood samples, from 36 healthy people, were collected with citrate anticoagulation tubes, mixing, and were centrifuged at 1000g for 10 min to separate plasma. The plasma was divided two portions, one for the detection of B antibody titers, the other for coagulation analysis.

The B antibody titers in the plasma were measured with the polybrene test according to the instruction (Baso Biological Technology Corporation, Zhuhai, China). Briefly, twofold serial dilutions of plasma sample from 1:2 were made with normal saline for each tube. The same volume of 2 % type Bred blood cells were added to each tube and mixed thoroughly. Low ionic medium, polybrene reagent and resuspending were added subsequently and operated based on the instruction, and the smallest dilution which could still agglutinate erythrocyte was determined as the endpoint, and its reciprocal was considered as the titer of the sample plasma.

In order to detect the effects of proteins MBPmut-OPS on blood clotting function, coagulation parameters of the samples treated/pre-treated with MBPmut-OPS were measured with fully automatic blood coagulation analyzer ACL7000 (BECKMAN, USA).

Adsorption of blood group B antibody in the plasma
Aliquots of plasma samples of 800 μL were mixed with final concentration of 0, 80, 160 and 320 μg/mL MBPmut-OPS, respectively. After incubation at room temperature for 1 h, the B antibody titer and clotting parameters in the plasma were detected as above methods.

Statistical analysis
The statistical analyses and figures were generated by GRAPHPAD PRISM software version 5.0. Data were shown as mean ± standard deviation (SD). The difference between two groups was compared by t test. For multiple comparisons, One-way ANOVA was used. A probability (P) value ≤ 0.05 was considered statistically significant.

Additional file

Additional file 1: Table S1. List of constructed plasmids, strains and primers used in the study. Figure S1. MALDI-TOF detection of MBPmut (a) and MBPmut-OPS (b).

Abbreviations
ABOi: ABO-incompatible; MBP: maltose binding protein; OPS: O-polysaccharides; LPS: Lipopolysaccharide; P: prothrombin time; APTT: activated partial thromboplastin time; TT: thrombin time; Fib: fibrinogen.

Authors’ contributions
WS carried out experiments, analyzed the primary data and drafted the manuscript. YZ, ZM and GY participated in the construction of the plasmids. YD knocked out the gene. DH and JL participated in the purification of the proteins. HZ, PGW, XL and MC supervised the whole research work and revised the manuscript. All authors read and approved the final manuscript.

Author details
1The State Key Laboratory of Microbial Technology, National Glycoengineering Research Center, School of Life Sciences and Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, Jinan, Shandong 250100, People’s Republic of China. 2The Institute of Medical Molecular Genetics, Department of Biochemistry and Molecular Biology, Bin Zhou Medical University, No. 346, Guan Hai Road, Lai Shan District, Yan Tai City, Shan Dong Province 264003, People’s Republic of China.

Acknowledgements
None.

Competing interests
The authors declare that they have no competing interests.
Availability of data and material
The datasets supporting the conclusions of this article are included within the article and its additional files.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of Shandong University School of Medicine (No. LL-201201067 and No. LL-201601037). The statements of ethics approval signed by the committee were provided.

Funding
This work was supported by Significant New Drugs Development (2012ZX093000-005), NSFC (No. 31270983, 3117033) and Natural Science Foundation of Shandong Province, China (NSFS, No. ZR2010CM057).

References
1. Muramatsu M, Gonzalez HD, Cacciola R, Aikawa A, Yaqoob MM, Puliatte C. ABO incompatible renal transplants: good or bad? World J Transplant. 2014;4:18–29.
2. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–30.
3. Yaich S. ABO‑Incompatible kidney transplantation. Saudi J Kidney Dis Transpl. 2013;24:463–72.
4. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantsations without splenectomy, using antigen‑specific immunoabsorption and rituximab. Am J Transplant. 2005;5:145–8.
5. Chikaishi H, Sasaki H, Tsutsumi H, Miyano S, Nakazawa R, Nakano T, Kita‑jima K, Kudo H, Takahashi T, Sato Y, Kimura K. ABO blood type incomp-tatable kidney transplantation without splenectomy prepared with plasma exchange and rituximab. Transplant Proc. 2008;40:3443–7.
6. Tyden G. The European experience. Transplantation. 2007;84:52–3.
7. Pryanov IM, Korchagina EY, Popova IS, Bovin NV. Block synthesis of A tet‑rasacharides (types 1, 3, and 4) related to the human ABO blood group system. Carbohydr Res. 2012;351:17–25.
8. Yi W, Shao J, Zhu L, Li M, Singh M, Lu Y, Lin S, Li H, Ryu K, Shen J, et al. Escherichia coli O86: Blood group B tetrasaccharide-structure and stepwise enzymatic synthesis of human blood group B antigen. J Am Chem Soc. 2005;127:2040–1.
9. Guo H, Yi W, Shao J, Lu Y, Zhang W, Song J, Wang PG. Molecular analysis of the O‑antigen gene cluster of Escherichia coli O86B7 and characterization of the chain length determinant gene (wzz). Appl Environ Microbiol. 2005;71:7995–8001.
10. Springer GF, Horton RE, Forbes M. Origin of anti-human blood group B agglutinins in white Leghorn chicks. J Exp Med. 1959;110:221–44.
11. Li M, Shen J, Liu X, Shao J, Yi W, Chow CS, Wang PG. Identification of a new alpha1,2-fucosyltransferase involved in O‑antigen biosynthesis of Escherichia coli O86B7 and formation of H‑type 3 blood group antigen. Biochemistry. 2008;47:11590–7.
12. Ihssen J, Kowarik M, Dilettoso S, Tanner C, Wacker M, Thony Meyer L. Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact. 2010;9:61.
13. Feldman MF, Wacker M, Hernandez M, Hitchin PG, Marolda CL, Kowarik M, Morris HR, Dell A, Valvano MA, Aebi M. Engineering N‑linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci USA. 2005;102:3016–21.
14. Walker KH, Hsieh PC, Rigs PG. Mutations in maltose-binding protein that alter affinity and solubility properties. Appl Microbiol Biotechnol. 2010;88:187–97.
15. Rodseth LE, Martineau P, Duplay P, Hofnung M, Quiocco FA. Crystalliza-tion of genetically engineered active maltose-binding proteins, including an immunogenic viral epitope insertion. J Mol Biol. 1990;213:607–11.
16. Islam ST, Lam JS. Synthesis of bacterial polysaccharides via the Wzx/Wzy-dependent pathway. Can J Microbiol. 2014;60:97–116.
17. Crew RJ, Ratner LE. ABO‑incompatible kidney transplantation: current practice and the decade ahead. Curr Opin Organ Transplant. 2010;15:526–30.
18. Springer GF, Williamson P, Brandes WC. Blood group activity of gram-negative bacteria. J Exp Med. 1961;113:1077–93.
19. al‑Hendy A, Toivanen P, Skurnik M. Rapid method for isolation and staining of bacterial lipopolysaccharide. Microbiol Immunol. 1991;35:331–3.